MedTrace Logo

Efficacy and Safety of Dihydroartemisinin-piperaquine (DHP) for the Treatment of Uncomplicated Malaria

NCT02353494 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2017-02-01

No results posted yet for this study

Summary

This is an observational safety and efficacy study on dihydroartemisinin-piperaquine in Timika, Indonesia with a 42 day follow up period.

Conditions

  • Plasmodium Falciparum Infection
  • Plasmodium Vivax Infection

Interventions

DRUG

Dihydroartemisinin-Piperaquine

Treatment according to national guidelines with follow up.

Sponsors & Collaborators

  • Eijkman Institute for Molecular Biology

    collaborator OTHER

  • World Health Organization

    collaborator OTHER

  • Menzies School of Health Research

    lead OTHER

Principal Investigators

  • Jeanne R Poespoprodjo, MD, PhD · Timika Research Facility Kompleks RSMM, Timika-Papua, Indonesia

Eligibility

Min Age
12 Months
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02353494 on ClinicalTrials.gov